A one-month supply of each covered insulin product carries a maximum out-of-pocket cost of $35 for Medicare drug-plan enrollees in 2026, and no deductible applies before that cap takes hold. The rule, created by the Inflation Reduction Act, means a retiree pays no more than $35 for a covered insulin even in the earliest days of the year, when other drugs might still be subject to a plan’s deductible. For the millions of older Americans who depend on insulin, the cap replaced a system in which a single vial could cost hundreds of dollars.
How the $35 insulin cap applies in 2026
The limit covers each covered insulin product an enrollee uses, priced per one-month supply. Someone who fills a 30-day supply pays at most $35; someone who fills a 90-day supply of the same insulin pays no more than $105, because the cap is calculated per month regardless of how many months are dispensed at once. The Centers for Medicare & Medicaid Services spells out this per-month, per-product structure in its guidance on the insulin benefit.
Before the cap, insulin costs varied widely by plan and by phase of coverage, and some enrollees who fell into the old coverage gap paid a large share of the list price out of pocket. List prices for common insulins had climbed for years, pushing some retirees to ration doses or skip fills, a practice clinicians warned could lead to hospitalizations. The flat $35 figure was designed to end that guesswork by fixing one price regardless of plan design or time of year.
The cap applies whether an enrollee has a stand-alone Part D plan or a Medicare Advantage plan that includes drug coverage. It also holds across every phase of the benefit, so the $35 ceiling does not disappear once a person moves past the initial coverage stage. That consistency is what distinguishes insulin from most other drugs, whose cost-sharing can shift as an enrollee’s total spending rises through the year.
Enrollees who qualify for the low-income subsidy known as Extra Help pay even less, with insulin costs running from $0 to a few dollars per prescription rather than the full $35. For everyone else, the $35 figure is the firm upper bound, and pharmacists are expected to charge no more than that for a covered product at the counter, even when a plan’s negotiated price for the drug is far higher.
Free retirement updates: Social Security and Medicare change every year, and nobody sends a memo. The free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
Why the absence of a deductible changes the math
Most Part D drugs can be subject to an annual deductible, an amount an enrollee pays in full before the plan begins sharing costs. Insulin is carved out of that rule: the Medicare coverage page for insulin confirms that no deductible applies, so the $35-a-month cap is in force from the first fill of January. A diabetic retiree does not have to burn through a deductible of several hundred dollars before the insulin protection begins.
That timing matters because January is when deductibles reset and drug costs spike for many enrollees. Without the carve-out, a person could face the full undiscounted price of insulin during the first weeks of the year, precisely when other medical bills also come due. By stripping the deductible out of the insulin calculation entirely, the rule keeps the cost flat and predictable across all twelve months.
The money spent on insulin also counts toward the broader $2,100 annual out-of-pocket maximum for covered Part D drugs, which took effect alongside the insulin cap under the same law. A retiree paying $35 a month sees those payments accumulate toward that ceiling, though at $420 a year for a single insulin, the insulin spending alone is unlikely to reach the cap without other costly prescriptions in the mix.
Where the $35 cap stops: formularies and pump-supplied insulin
The protection applies only to insulins a plan actually covers. A plan’s formulary determines which specific products qualify, so an enrollee whose preferred brand is left off the list may not get the $35 price on that exact product and could need to switch to a covered alternative or seek an exception. Comparing formularies during the fall open-enrollment window is the step that determines whether a person’s own insulin falls under the cap.
When a needed insulin is not on the formulary, enrollees can ask the plan for a coverage exception, a formal request that, if granted, brings the drug under the plan’s coverage and the $35 cap. The process requires the prescriber to explain why the covered alternatives are unsuitable, and plans must respond within set timeframes. Until an exception is approved, though, the enrollee has no guarantee of the capped price on the non-covered product.
A separate wrinkle affects insulin delivered through a durable medical equipment pump, which Medicare covers under Part B rather than Part D. The Inflation Reduction Act extended a $35 monthly cap to that Part B insulin as well, but it runs through a different part of the program with its own rules and suppliers. Retirees who use a pump should confirm which part of Medicare is paying, because the paperwork and the supplier network differ even though the dollar figure lines up.
The insulin cap is one of the few Medicare changes that delivers an unambiguous, easy-to-verify number: no covered insulin should cost more than $35 for a month’s supply, with nothing owed toward a deductible first. The remaining uncertainty lives in the formulary — whether a given brand is covered — and in the Part B pump track, which reaches the same price by a different route. For a retiree, the practical task is confirming that a specific insulin sits on a specific plan’s covered list before assuming the $35 applies.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
